Video

ecancer's extensive video archive features interviews, panel discussions and conference coverage on almost every topic in oncology.
Phase II study of blinatumomab for MRD-positive B-cell acute lymphoblastic leuka...
Prof Nicholas Short - The University of Texas MD Anderson Cancer Center, Houston...
Phase II study of blinatumomab for MRD-positive B-cell acute lymphoblastic leukaemia ( Prof Nicholas Short - The University of Texas MD Anderson Cancer Center, Houston, USA )
17 Jun 2021
EHA 2021: Latest in immunotherapy for R/R multiple myeloma
Prof Evangelos Terpos, Prof Heinz Ludwig, Prof Meral Beksac and Prof Michele Cav...
EHA 2021: Latest in immunotherapy for R/R multiple myeloma ( Prof Evangelos Terpos, Prof Heinz Ludwig, Prof Meral Beksac and Prof Michele Cavo )
17 Jun 2021
OncoAlert and ecancer ASCO roundup - Day 4 and 5
Dr Gil Morgan - Skåne University Hospital in Lund, Sweden
OncoAlert and ecancer ASCO roundup - Day 4 and 5 ( Dr Gil Morgan - Skåne University Hospital in Lund, Sweden )
16 Jun 2021
A comparison of clinical outcomes from ZUMA-5 and the international scholar-5 ex...
Prof Paola Ghione - Roswell Park Comprehensive Cancer Center, Buffalo, USA
A comparison of clinical outcomes from ZUMA-5 and the international scholar-5 external control cohort in R/R FL ( Prof Paola Ghione - Roswell Park Comprehensive Cancer Center, Buffalo, USA )
15 Jun 2021
Pembrolizumab plus trastuzumab and chemotherapy for HER2+ metastatic gastric or ...
Dr Yelena Janjigian - Memorial Sloan Kettering Center, New York, USA
Pembrolizumab plus trastuzumab and chemotherapy for HER2+ metastatic gastric or gastroesophageal junction cancer ( Dr Yelena Janjigian - Memorial Sloan Kettering Center, New York, USA )
14 Jun 2021
Real world evidence on the use of antibody drug conjugates in peripheral T-cell ...
Prof Ali Bazarbachi - American University of Beirut-Medical Center, Beirut, Leba...
Real world evidence on the use of antibody drug conjugates in peripheral T-cell lymphoma ( Prof Ali Bazarbachi - American University of Beirut-Medical Center, Beirut, Lebanon )
14 Jun 2021
Patritumab deruxtecan (HER3-DXd) in EGFR inhibitor-resistant, EGFR-mutated NSCLC
Dr Christina Baik - University of Washington School of Medicine, Seattle, USA
Patritumab deruxtecan (HER3-DXd) in EGFR inhibitor-resistant, EGFR-mutated NSCLC ( Dr Christina Baik - University of Washington School of Medicine, Seattle, USA )
11 Jun 2021
ELEVATE-TN: Acalabrutinib ± obinutuzumab versus obinutuzumab + chlorambucil in t...
Dr Jeff Sharman - Willamette Valley Cancer Institute, Eugene, USA
ELEVATE-TN: Acalabrutinib ± obinutuzumab versus obinutuzumab + chlorambucil in treatment-naïve CLL - Four-year follow up ( Dr Jeff Sharman - Willamette Valley Cancer Institute, Eugene, USA )
11 Jun 2021
IMpower010: Atezolizumab versus best supportive care after adjuvant chemotherapy...
Prof Heather Wakelee - Stanford University, Stanford, USA
IMpower010: Atezolizumab versus best supportive care after adjuvant chemotherapy in resected NSCLC ( Prof Heather Wakelee - Stanford University, Stanford, USA )
11 Jun 2021
AL3818 hydrochloride monotherapy in subjects with metastatic or advanced synovia...
Prof Brian Van Tine - Washington University in St. Louis, St. Louis, USA
AL3818 hydrochloride monotherapy in subjects with metastatic or advanced synovial sarcoma ( Prof Brian Van Tine - Washington University in St. Louis, St. Louis, USA )
10 Jun 2021
CAPTIVATE: Fixed-duration first-line treatment with ibrutinib plus venetoclax fo...
Dr Rajat Bannerji - Rutgers Cancer Institute of New Jersey/RWJBarnabas Health, N...
CAPTIVATE: Fixed-duration first-line treatment with ibrutinib plus venetoclax for CLL/SLL ( Dr Rajat Bannerji - Rutgers Cancer Institute of New Jersey/RWJBarnabas Health, New Jersey, USA )
10 Jun 2021
CodeBreaK100: Sotorasib in pretreated KRAS p.G12C mNSCLC
Dr Ferdinandos Skoulidis - MD Anderson Cancer Center, Houston, USA
CodeBreaK100: Sotorasib in pretreated KRAS p.G12C mNSCLC ( Dr Ferdinandos Skoulidis - MD Anderson Cancer Center, Houston, USA )
9 Jun 2021